ALK4290 (AKST4290) is a potent, orally active and selective CCR3 inhibitor with a Ki of 3.2 nM. ALK4290 blocks CCR3 -mediated signaling, abrogates macrophage supernatant-driven mesothelial-to-mesenchymal transition, and decreases p38 phosphorylation. ALK4290 inhibits CCL26-CCR3 axis-driven GPX2-mediated B-cell activation, and targets B cells to inhibit activation by GPX2 -overexpressing tumor cells. ALK4290 can be used for the research of hepatocellular carcinome and Parkinson’s disease.
Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Cancer | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CCR
感谢您来到爆牛贸易,请为我们留言或者使用以下方式联系我们,我们将尽快给您回复,并为您提供最真诚的服务,谢谢。